Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan
- PMID: 19944790
- DOI: 10.1016/j.vaccine.2009.11.029
Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan
Abstract
Herpes zoster, a common disease, has an important impact on the health of adults, particularly the elderly, and the health system. This study evaluated the disease burden and epidemiological characteristics of herpes zoster in Taiwan. Using herpes zoster-related ICD-9-CM codes used on Taiwan's National Health Insurance claims, we analyzed overall and age group differences in incidence, complications, utilization of healthcare facilities, lengths of stay, and cost of their medical care in Taiwan's population from 2000 to 2005. The overall annual incidence of zoster was 4.97 cases per 1000 people, with women having a significantly higher incidence than men (5.20 per 1000 vs. 4.72 per 1000, p<0.001). The incidence increased stepwise with age, with 5.18 cases per 1000 in people 40-50 years old, 8.36 in those 50-60, 11.09 in those 60-70, and 11.77 in those above 70 years old. The estimated lifetime risk of developing herpes zoster was 32.2%. Zoster-related hospitalizations and medical cost per patient increased with age. In conclusion, about two-thirds of Taiwan's zoster cases occur in adults older than 40 years old and about one-third of the population would develop zoster within their lifetime.
(c) 2009 Elsevier Ltd. All rights reserved.
Similar articles
-
Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006.Acta Derm Venereol. 2009 Nov;89(6):612-6. doi: 10.2340/00015555-0729. Acta Derm Venereol. 2009. PMID: 19997693
-
Disease burden of herpes zoster in Korea.J Clin Virol. 2010 Apr;47(4):325-9. doi: 10.1016/j.jcv.2010.01.003. Epub 2010 Feb 24. J Clin Virol. 2010. PMID: 20181512
-
Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.Vaccine. 2007 Nov 28;25(49):8326-37. doi: 10.1016/j.vaccine.2007.09.066. Epub 2007 Oct 17. Vaccine. 2007. PMID: 17980938
-
Herpes zoster: epidemiology, natural history, and common complications.J Am Acad Dermatol. 2007 Dec;57(6 Suppl):S130-5. doi: 10.1016/j.jaad.2007.08.046. J Am Acad Dermatol. 2007. PMID: 18021864 Review.
-
Herpes zoster vaccination: benefits and barriers.J Am Osteopath Assoc. 2009 Jun;109(6 Suppl 2):S22-4. J Am Osteopath Assoc. 2009. PMID: 19553633 Review.
Cited by
-
The Shozu Herpes Zoster (SHEZ) study: rationale, design, and description of a prospective cohort study.J Epidemiol. 2012;22(2):167-74. doi: 10.2188/jea.je20110035. Epub 2012 Feb 18. J Epidemiol. 2012. PMID: 22343323 Free PMC article.
-
Public health impact of herpes zoster vaccination on older adults in Hong Kong.Hum Vaccin Immunother. 2023 Dec 31;19(1):2176065. doi: 10.1080/21645515.2023.2176065. Epub 2023 Feb 28. Hum Vaccin Immunother. 2023. PMID: 36854447 Free PMC article.
-
Herpes Zoster and Cardiovascular Disease: Exploring Associations and Preventive Measures through Vaccination.Vaccines (Basel). 2024 Feb 28;12(3):252. doi: 10.3390/vaccines12030252. Vaccines (Basel). 2024. PMID: 38543886 Free PMC article. Review.
-
Evaluation of the economic burden of Herpes Zoster (HZ) infection.Hum Vaccin Immunother. 2015;11(1):245-62. doi: 10.4161/hv.36160. Hum Vaccin Immunother. 2015. PMID: 25483704 Free PMC article.
-
Herpes zoster and long-term vascular risk: a retrospective cohort study.Sci Rep. 2023 Feb 9;13(1):2364. doi: 10.1038/s41598-023-29667-w. Sci Rep. 2023. PMID: 36759695 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical